Ranking  1 in the International Index of Erectile Function (IIEF EF)!
- A challenge to normalization of erectile function by fundamentally treating erectile dysfunctions
- Minimization of existing side effects such as color sense troubles, etc. with high selectivity
- SK chemicals, proving that it is a representative enterprise for development of new drugs, with its 3rd development of new drugs

A new drug for treating erectile dysfunctions with minimization of side effects of existing erectile dysfunction treatment drugs while showing the strongest erectile effect in the world has been born by our research team

Especially, Mvix has acquired a high score of 25.7 points out of a possible 30 in the measurement of the international index of erectile functions (IIEF EF), an international index to indicate the efficacy of erectile dysfunction treatment drugs, so as to obtain the highest score in history by putting existing drugs out of the way. (26 or more points of IIEF EF may be in the [normal erectile function] level)

Besides, as an effect of fundamental erectile dysfunction treatment rather than temporary symptom improvement, among the patient group that had freely taken it for more than 12 weeks, the normal erectile function recovery rate reached 46%, an excellent effect.
Meanwhile, in the clinical test by Covance in UK and the efficacy examination by MDS Phama in U.S., Mvix showed only a little face flushing and headache in terms of safety so as to report remarkably lower side effect occurrence rate than existing competing products and report no heart related side effects, which is more excellent safety than existing erectile dysfunction treatment drugs.

Mvix less suppresses PDE-1 and PDE-6 due to high selectivity to PDE-5 as compared with other PDE-5 starch blockers such as Viagra, etc., so as to show less headache, which is a general side effect of existing erectile dysfunction treatment drug, and report no color sense troubles.

Having been 33.3 billion won in 2001, the entire market scale of domestic erectile dysfunction treatment drugs was 64 billion won in 2004, 70.5 billion won in 2005 and 77 billion won (36.5 billion won for Viagra, 22.5 billion won for Cialis, 9.6 billion won for Zydena, etc./IMS data) in 2006, which recorded a high growth rate of over 10% a year, and Mvix is expecting about 10 billion won of sales in 2008.

SK chemicals has completed registration of Chinese trade mark name(愛比獅 Aibishi) in order to advance into the Chinese erectile dysfunction treatment drug markets of 450 billion won(4 billion RMB) scales, is proceeding with local marketing through the SK Pharma Beijing(Beijing, Tianjin, Shanghai), an affiliate of SK chemicals, and is expecting local sales of over 10 billion won from 2009 when the advancement of Mvix becomes serious.

Meanwhile, with the development of Mvix at this time, SK chemicals has realized a heroic deed to notify the excellence of our life science and technology to the inside and outside of the country as well as reconfirm the position of Korea’s life science R&D as the eldest son by succeeding in the 3rd independent development of new drugs for the first time in Korea, following the success in the development of an anti-cancer medicine [Sunpla], the No.1 new drug in Korea, in 1999 and the development of an arthritis treatment drug[Joins], the No.1 new natural drug in Korea, in 2001.

Seung-Gwon Shin, CEO in the life science part of SK chemicals, said, “Mvix was developed with a view to a happy drug to satisfy both of efficacy and safety” and “it will be going to pursue real home happiness through couple love by taking a position as a pronoun of home erectile dysfunction treatment drugs in the overseas markets as well as domestic markets.
Currently, Mvix is securing intellectual property rights by registering and applying material patents to 38 nations in the world such as United States, EU, China, Japan, etc. and is promoting technology exports to major nations such as China, etc. as well as selling it in domestic markets. <The end>

⊙ Seong-Woo Kim, a manger of press PR of SK chemicals( H: 011-248-5308 ), / Joon-Ho Jung, an assistant manager(H:016-581-9717)

.....................................................Attachments.............................................................

1. Interpretation of terminology
The International Index of Erectile Function(IIEF)
The international index of erectile function(IIEF) is a self-evaluation method to enable composite measurement of sexual functions being used most basically to evaluate male’s sexual functions by describing 5 kinds of domains(erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction) related to male’s sexual functions.

IIEF is being promoted as a major evaluation variable to diagnostically evaluate event a serious illness of ED as well as a clinical test of ED(erectile dysfunction) in the world. IIEF was first developed in association with a clinical test program of sildenafil (Vigra) and is currently being adopted as a ‘gold standard’ measurement method to evaluate validity in the clinical test of ED. Translated into 32 languages including Korean, IIEF was proved in terms of reliability and appropriateness so as to be used as a major validity evaluation variable in over 50 clinical tests.

IIEF can measure up to psychological part of sexual functions, is being continuously adopted in random clinical tests of sildenafil and other ED treatment drugs, and is widely used to classify the seriousness of ED and the prevalence rate of illness, according to the reports in various papers. Besides, this shows consistent and firm treatment reactions in the research proceeded with in various etiological small groups as well as United States, Europe and Asia. Like this, IIEF is an evaluation method to show high sensitivity and specificity satisfying the psychological evaluation criteria of ED clinical tests reliably and appropriately.